In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating mogamulizumab versus vorinostat in patients with T-cell lymphoma
In a nutshell This study compared the effectiveness of mogamulizumab (Poteligeo) versus vorinostat (Zolinza) in patients with previously treated cutaneous (skin) T-cell lymphoma (CTCL). This study concluded that mogamulizumab was well-tolerated and significantly more effective than vorinostat in these patients. Some background CTCL is a rare type of...
Read MoreComparing duvelisib and ofatumumab in chronic lymphocytic leukemia
In a nutshell This study aimed to compare the safety and effectiveness of duvelisib (Copiktra) and ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that duvelisib was an effective treatment option for these patients. Some background Chronic lymphocytic leukemia (CLL) is the most common...
Read MoreIs chemotherapy before transplantation safe and effective in AML?
In a nutshell The study looked at the safety and effectiveness of combining different chemotherapy drugs followed by stem-cell transplant for the treatment of unresponsive acute myeloid leukemia (AML). Researchers found that this method was safe and effective in the patients studied. Some background Acute myeloid leukemia is a cancer of the bone...
Read MoreCan prednisone be replaced with dexamethasone in patients with prostate cancer treated with abiraterone acetate?
In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...
Read MoreEvaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma
In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...
Read MoreEvaluating venetoclax monotherapy for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...
Read MoreEvaluating R-CyBorD for the treatment of relapsed non-Hodgkin’s lymphoma
In a nutshell This study evaluated the effectiveness and safety of the R-CyBorD (rituximab, cyclophosphamide, bortezomib, dexamethasone) regimen in patients with relapsed indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated in these patients. Some background There are many...
Read MoreSequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine
In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...
Read MoreNew treatment options for patients with relapsed Hodgkin’s lymphoma
In a nutshell This article reviewed new treatment options for patients with relapsed Hodgkin’s lymphoma (HL). Some background The most common front-line (primary) chemotherapy regimen for the treatment of HL is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 88 – 94% of patients with HL respond to this treatment. However, 10...
Read MoreCan T-cell therapy treat unresponsive ALL?
In a nutshell This study looked at the current evidence for the effect of changing genes in T-cells (a type of immune cell) to target cancer cells in acute lymphoblastic leukemia (ALL). The study found that these T-cells were safe and effective in the treatment of ALL. Some background Acute Lymphoblastic Leukemia is a type of bone marrow cancer...
Read MoreTreatment options for patients with relapsed or refractory MCL
In a nutshell This article reviewed different treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) mantle cell lymphoma (MCL). Some background Chemoimmunotherapy is the typical first-line (primary) treatment for patients with MCL. 80 – 90% of patients respond to treatment, but many...
Read More
